This site is intended for healthcare professionals
Optimising anti-TNF treatment using biosimilars Learning Zone

Expert Opinion

Know the latest insights on the use of αTNF biosimilars in rheumatoid arthritis? Watch these videos on treatment initation and optimisation.

Biological disease-modifying antirheumatic drugs (DMARDs), such as anti tumour necrosis factor (αTNF), are an important component of treatment for patients with rheumatic diseases1.

In this illuminating interview, Professor Thomas Dörner explores the role of αTNF biosimilars in rheumatoid arthritis, including the use of biomarkers, therapeutic drug monitoring (TDM) and diagnostic techniques.

The impact of rheumatoid arthritis

Discover how patients are personally impacted by rheumatoid arthritis through loss of function, being unable to work and more. Also learn about the impact of coronavirus disease 2019 (COVID-19), from patient anxiety to the potential risks of immunosuppresive agents.

Factors that influence the initiation of biologic treatments

Register free for full access to medthority.com

Treating rheumatoid arthritis with αTNF biosimilars

Examine the use of αTNF biosimilars for the treatment of rheumatoid arthritis and learn how they currently fit into the European League Against Rheumatism (EULAR), American College of Rheumatology (ACR) and British Society for Rheumatology (BSPR) guidelines.

Biomarkers for αTNF treatment response

Register free for full access to medthority.com

Meet the expert

Meet out expert Professor Thomas Dörner, a board certified Rheumatologist and Professor of Rheumatology and Hemostaseology at Charité University Hospitals, Berlin, Germany.

References

  1. Smolen JS, Goncalves J, Quinn M, Benedetti F, Lee JY. Era of biosimilars in rheumatology: Reshaping the healthcare environment. RMD Open. 2019;5(1):900.
Register free for full access to medthority.com

Welcome: